Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.212x

Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has a cash flow conversion efficiency ratio of -0.212x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-19.96 Million ≈ $-2.92 Million USD) by net assets (CN¥94.30 Million ≈ $13.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Hangzhou TianMuShan Pharmaceutical Enter to measure how many days the company can operate on defensive assets alone.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)

This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
BRC Group Holdings, Inc.
NASDAQ:RILY
1.643x
New Providence Acquisition Corp. III Class A Ordinary Shares
NASDAQ:NPAC
-0.001x
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
0.134x
Patel Engineering Limited
NSE:PATELENG
0.097x
Unitech Computer Co Ltd
TW:2414
0.057x
Ld Intelligent Technology Co Ltd
SHE:300883
0.008x
Tus Pharmaceutical Group Co Ltd
SHE:000590
0.004x
Global Standard Technology Limited
KQ:083450
0.015x

Annual Cash Flow Conversion Efficiency for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1998–2025)

The table below shows the annual cash flow conversion efficiency of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Hangzhou TianMuShan Pharmaceutical Enter (600671) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥93.99 Million
≈ $13.75 Million
CN¥11.79 Million
≈ $1.73 Million
0.125x +129.08%
2024-12-31 CN¥85.02 Million
≈ $12.44 Million
CN¥-36.67 Million
≈ $-5.37 Million
-0.431x -18.14%
2023-12-31 CN¥55.95 Million
≈ $8.19 Million
CN¥-20.43 Million
≈ $-2.99 Million
-0.365x +91.56%
2022-12-31 CN¥4.48 Million
≈ $655.53K
CN¥-19.37 Million
≈ $-2.83 Million
-4.324x -956.52%
2021-12-31 CN¥64.56 Million
≈ $9.45 Million
CN¥-26.42 Million
≈ $-3.87 Million
-0.409x -354.96%
2020-12-31 CN¥93.33 Million
≈ $13.66 Million
CN¥-8.40 Million
≈ $-1.23 Million
-0.090x -107.44%
2019-12-31 CN¥133.33 Million
≈ $19.51 Million
CN¥161.13 Million
≈ $23.58 Million
1.209x +39.51%
2018-12-31 CN¥81.62 Million
≈ $11.94 Million
CN¥70.71 Million
≈ $10.35 Million
0.866x +240.09%
2017-12-31 CN¥96.27 Million
≈ $14.09 Million
CN¥24.52 Million
≈ $3.59 Million
0.255x +949.12%
2016-12-31 CN¥66.18 Million
≈ $9.68 Million
CN¥1.61 Million
≈ $235.13K
0.024x +203.93%
2015-12-31 CN¥62.76 Million
≈ $9.18 Million
CN¥-1.47 Million
≈ $-214.52K
-0.023x -404.59%
2014-12-31 CN¥85.25 Million
≈ $12.47 Million
CN¥653.79K
≈ $95.67K
0.008x -94.10%
2013-12-31 CN¥95.26 Million
≈ $13.94 Million
CN¥12.37 Million
≈ $1.81 Million
0.130x +160.78%
2012-12-31 CN¥92.76 Million
≈ $13.57 Million
CN¥-19.82 Million
≈ $-2.90 Million
-0.214x -501.81%
2011-12-31 CN¥182.84 Million
≈ $26.75 Million
CN¥-6.49 Million
≈ $-950.05K
-0.036x +56.56%
2010-12-31 CN¥154.14 Million
≈ $22.55 Million
CN¥-12.60 Million
≈ $-1.84 Million
-0.082x -302.37%
2009-12-31 CN¥187.74 Million
≈ $27.47 Million
CN¥7.58 Million
≈ $1.11 Million
0.040x -54.19%
2008-12-31 CN¥240.30 Million
≈ $35.16 Million
CN¥21.19 Million
≈ $3.10 Million
0.088x -47.51%
2007-12-31 CN¥282.93 Million
≈ $41.40 Million
CN¥47.53 Million
≈ $6.96 Million
0.168x -28.28%
2006-12-31 CN¥236.44 Million
≈ $34.60 Million
CN¥55.39 Million
≈ $8.10 Million
0.234x +561.08%
2005-12-31 CN¥239.39 Million
≈ $35.03 Million
CN¥8.48 Million
≈ $1.24 Million
0.035x +560.32%
2004-12-31 CN¥252.36 Million
≈ $36.93 Million
CN¥1.35 Million
≈ $198.17K
0.005x +103.17%
2003-12-31 CN¥242.64 Million
≈ $35.51 Million
CN¥-41.13 Million
≈ $-6.02 Million
-0.170x -296.91%
2002-12-31 CN¥253.20 Million
≈ $37.05 Million
CN¥21.80 Million
≈ $3.19 Million
0.086x +105.99%
2001-12-31 CN¥251.63 Million
≈ $36.82 Million
CN¥10.52 Million
≈ $1.54 Million
0.042x +208.63%
2000-12-31 CN¥251.29 Million
≈ $36.77 Million
CN¥-9.67 Million
≈ $-1.41 Million
-0.038x -119.13%
1999-12-31 CN¥244.10 Million
≈ $35.72 Million
CN¥49.09 Million
≈ $7.18 Million
0.201x +1911.55%
1998-12-31 CN¥235.71 Million
≈ $34.49 Million
CN¥2.36 Million
≈ $344.84K
0.010x --

About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

SHG:600671 China Drug Manufacturers - General
Market Cap
$320.05 Million
CN¥2.19 Billion CNY
Market Cap Rank
#14598 Global
#4355 in China
Share Price
CN¥17.96
Change (1 day)
+9.98%
52-Week Range
CN¥13.07 - CN¥22.50
All Time High
CN¥37.82
About

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared sl… Read more